A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
APTARGROUP, INC.
ATR
$8.8B
Mkt Cap
$132.36
+2.60%
APTARGROUP, INC. (ATR) has a current P/E ratio of 22.5, compared to its historical median P/E of 28.4. The stock is currently considered Cheap based on its historical valuation range.
APTARGROUP, INC. (ATR) has a 5-year average return on invested capital (ROIC) of 10.2%. This indicates solid capital allocation.
APTARGROUP, INC. (ATR) has a market capitalization of $9.7B. It is classified as a mid-cap stock.
Yes, APTARGROUP, INC. (ATR) pays a dividend with a trailing twelve-month yield of 1.26%. The company also returns capital through share buybacks, with a buyback yield of 3.98%.
Based on historical P/E analysis, APTARGROUP, INC. (ATR) appears cheap. The current P/E of 22.5 is 21% below its historical median of 28.4. The estimated fair value CAGR (P/E method) is 8.4%.
APTARGROUP, INC. (ATR) operates in the Plastics Products, Nec industry, within the Materials sector.
APTARGROUP, INC. (ATR) reported annual revenue of $3.8 billion in its most recent fiscal year, based on SEC EDGAR filings.
Aptar is a global leader in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies serving diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. The company operates through proprietary design, engineering, materials science, and manufacturing capabilities, with approximately 14,000 employees across approximately 20 countries and manufacturing facilities in North America, Europe, Asia, and Latin America. Primary products include dispensing pumps (finger-actuated systems for sprays, liquids, and lotions), closures (dispensing and non-dispensing solutions), aerosol valves (for pressurized containers), elastomeric primary packaging components (stoppers, plungers, needle shields, and pre-filled syringe components), active material science solutions (polymer-based technologies for impurity mitigation and product stability), and digital health solutions (regulated software, connected devices, and diagnostic tools for treatment adherence and disease management). The company serves approximately 5,000 customers with no single customer or group accounting for greater than 4% of net sales, and generates revenue through a combination of repeat business (approximately 90% of revenue) and new product pipeline contributions (approximately 7–10% of revenue annually), with customers increasingly preferring dispensing formats over non-dispensing formats for convenience, product differentiation, shelf appeal, and dosage accuracy.
【Pharma growth resuming, margins recovering】 Management expects continued strength across the pharma portfolio excluding emergency medicine, with prescription division returning to healthy growth in the second quarter and beyond, supported by strong momentum in injectables, systemic nasal drug delivery, and consumer healthcare solutions. The company anticipates sequential margin improvements in beauty and closures segments through the second half of 2026 as production cost headwinds and product mix challenges abate, with full-year adjusted EBITDA margins expected to remain within the company's long-term target range of 32–36%. Capital investments for full year 2026 are expected to be in the range of $260–280 million, and management remains focused on executing a rigorous productivity roadmap to address near-term headwinds while driving further operational efficiencies and supply chain optimization. The emergency medicine destocking headwind of approximately $65 million is expected to be more pronounced in the first half of 2026, with the impact moderating in the second half, after which the company expects to establish a new baseline from which low to mid-single-digit growth is anticipated.
| Metric | Target | Period |
|---|---|---|
| Capital investments | $260–280 million | FY2026 |
| Depreciation and amortization expense | $310–320 million | FY2026 |
| Emergency medicine revenue decline | approximately $65 million | FY2026 |
Capital investments (FY2026): “For full year 2026, capital investments are expected to be in the range of $260 to 280 million.”
Depreciation and amortization expense (FY2026): “Depreciation and amortization expense is now expected to be between $310 million and $320 million.”
Emergency medicine revenue decline (FY2026): “our previously communicated estimate that emergency medicine sales would decline by approximately $65 million in full year 2026 continues to track”
Generated solely from the company's own reports listed below — not from third-party data. Hallucination risk is low. · Sources: 10-K, Q4 FY2025 Earnings Call, Q3 FY2025 Earnings Call, Q2 FY2025 Earnings Call, Q1 FY2025 Earnings Call
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 3.9B | 3.8B | 3.6B | 3.5B | 3.3B | 3.2B |
| Net Income | 387M | 393M | 375M | 284M | 239M | 244M |
| EPS | $5.31 | $5.89 | $5.53 | $4.25 | $3.59 | $3.61 |
| Free Cash Flow | 327M | 300M | 367M | 263M | 168M | 56M |
| ROIC | 10.6% | 11.4% | 12.2% | 9.7% | 8.9% | 9.0% |
| Gross Margin | - | 24.8% | 24.4% | 22.5% | 22.5% | 22.1% |
| Debt/Equity | 0.52 | 0.56 | 0.42 | 0.49 | 0.57 | 0.64 |
| Dividends/Share | $1.67 | $1.83 | $1.72 | $1.58 | $1.52 | $1.50 |
| Operating Income | 495M | 501M | 496M | 404M | 379M | 347M |
| Operating Margin | 12.8% | 13.3% | 13.9% | 11.6% | 11.4% | 10.8% |
| ROE | 14.7% | 15.3% | 15.7% | 13.0% | 11.9% | 12.8% |
| Shares Outstanding | 73M | 67M | 68M | 67M | 67M | 68M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 2.6B | 2.3B | 2.3B | 2.5B | 2.8B | 2.9B | 2.9B | 3.2B | 3.3B | 3.5B | 3.6B | 3.8B | 3.9B |
| Gross Margin | 26.8% | 29.3% | 29.5% | 29.3% | 28.8% | 30.6% | 30.9% | 22.1% | 22.5% | 22.5% | 24.4% | 24.8% | N/A |
| R&D | 76M | 67M | 66M | 68M | 75M | 83M | 93M | 100M | 94M | 93M | 96M | 105M | 105M |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 2.8B | 3.0B | 3.0B |
| EBIT | 306M | 324M | 314M | 323M | 286M | 372M | 339M | 347M | 379M | 404M | 496M | 501M | 495M |
| Op. Margin | 11.8% | 14.0% | 13.5% | 13.1% | 10.4% | 13.0% | 11.6% | 10.8% | 11.4% | 11.6% | 13.9% | 13.3% | 12.8% |
| Net Income | 192M | 199M | 206M | 220M | 195M | 242M | 214M | 244M | 239M | 284M | 375M | 393M | 387M |
| Net Margin | 7.4% | 8.6% | 8.8% | 8.9% | 7.0% | 8.5% | 7.3% | 7.6% | 7.2% | 8.2% | 10.5% | 10.4% | 10.0% |
| Non-Recurring | 0 | 0 | 348K | 1.8M | 65M | 20M | 24M | 23M | 6.2M | 49M | 13M | 9.1M | 8.9M |
| Returns on Capital | |||||||||||||
| ROIC | 14.6% | 16.9% | 17.4% | 15.9% | 9.7% | 10.6% | 9.2% | 9.0% | 8.9% | 9.7% | 12.2% | 11.4% | 10.6% |
| ROE | 14.8% | 17.7% | 17.7% | 17.7% | 14.2% | 16.2% | 12.5% | 12.8% | 11.9% | 13.0% | 15.7% | 15.3% | 14.7% |
| ROA | 7.8% | 8.2% | 8.2% | 7.7% | 6.0% | 7.0% | 5.7% | 6.0% | 5.7% | 6.6% | 8.4% | 8.1% | 7.6% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 316M | 324M | 325M | 325M | 314M | 514M | 570M | 363M | 479M | 575M | 643M | 570M | 606M |
| Free Cash Flow | 154M | 174M | 196M | 168M | 102M | 272M | 324M | 56M | 168M | 263M | 367M | 300M | 327M |
| Owner Earnings | 144M | 164M | 151M | 153M | 122M | 296M | 316M | 90M | 204M | 285M | 332M | 239M | 267M |
| CapEx | 162M | 149M | 129M | 157M | 211M | 242M | 246M | 308M | 310M | 312M | 276M | 270M | 279M |
| Maint. CapEx | 152M | 139M | 155M | 153M | 172M | 195M | 220M | 235M | 234M | 249M | 264M | 287M | 297M |
| Growth CapEx | 9.7M | 10M | 0 | 3.5M | 40M | 48M | 26M | 73M | 77M | 64M | 13M | 0 | 0 |
| D&A | 152M | 139M | 155M | 153M | 172M | 195M | 220M | 235M | 234M | 249M | 264M | 287M | 297M |
| CapEx/OCF | 51.2% | 46.0% | 39.7% | 48.2% | 67.4% | 47.1% | 43.1% | 84.7% | 64.9% | 54.3% | 43.0% | 47.4% | 46.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 71M | 71M | 77M | 80M | 82M | 90M | 93M | 99M | 99M | 104M | 114M | 121M | 122M |
| Dividend Yield | 1.9% | 1.9% | 1.8% | 1.7% | 1.4% | 1.3% | 1.3% | 1.1% | 1.4% | 1.3% | 1.2% | 1.3% | 1.3% |
| Share Buybacks | 341M | 0 | 0 | 121M | 3.9M | 86M | 0 | 78M | 92M | 48M | 69M | 365M | 385M |
| Buyback Yield | 8.7% | N/A | N/A | 2.4% | 0.1% | 1.2% | N/A | 1.0% | 1.3% | 0.6% | 0.7% | 4.5% | 4.0% |
| Stock-Based Comp | 20M | 21M | 20M | 19M | 20M | 24M | 34M | 39M | 41M | 41M | 48M | 44M | 42M |
| Debt Repayment | 778K | 17M | 55M | 166M | 72M | 67M | 65M | 69M | 265M | 126M | 374M | 167M | 167M |
| Balance Sheet | |||||||||||||
| Net Debt | 41M | 298M | 14M | 545M | 1.0B | 954M | 872M | 1.1B | 1.0B | 916M | 800M | 1.1B | 1.1B |
| Cash & Equiv. | 400M | 490M | 466M | 713M | 262M | 242M | 300M | 123M | 142M | 224M | 224M | 402M | 229M |
| Long-Term Debt | 589M | 761M | 773M | 1.2B | 1.1B | 1.1B | 1.1B | 907M | 1.1B | 681M | 688M | 1.1B | 1.1B |
| Debt/Equity | 0.76 | 0.71 | 0.81 | 0.96 | 0.91 | 0.76 | 0.63 | 0.64 | 0.57 | 0.49 | 0.42 | 0.56 | 0.52 |
| Interest Coverage | 14.6 | 9.4 | 8.9 | 8.0 | 8.8 | 10.5 | 10.2 | 11.5 | 9.3 | 10.0 | 11.3 | 9.5 | 393.2 |
| Equity | 1.1B | 1.1B | 1.2B | 1.3B | 1.4B | 1.6B | 1.9B | 2.0B | 2.1B | 2.3B | 2.5B | 2.7B | 2.6B |
| Total Assets | 2.4B | 2.4B | 2.6B | 3.1B | 3.4B | 3.6B | 4.0B | 4.1B | 4.2B | 4.5B | 4.4B | 5.3B | 5.1B |
| Total Liabilities | 1.3B | 1.3B | 1.4B | 1.8B | 2.0B | 2.0B | 2.1B | 2.2B | 2.1B | 2.1B | 1.9B | 2.6B | 28M |
| Intangibles | 40M | 32M | 94M | 95M | 255M | 291M | 344M | 362M | 316M | 283M | 255M | 255M | 245M |
| Retained Earnings | 1.7B | 1.2B | 1.2B | 1.3B | 1.4B | 1.5B | 1.6B | 1.8B | 1.9B | 2.1B | 2.4B | 2.6B | 2.7B |
| Working Capital | 609M | 883M | 727M | 1.1B | 642M | 608M | 589M | 376M | 513M | 298M | 410M | 727M | 705M |
| Current Assets | 1.2B | 1.3B | 1.3B | 1.7B | 1.3B | 1.3B | 1.4B | 1.4B | 1.4B | 1.5B | 1.5B | 1.9B | 1.8B |
| Current Liabilities | 605M | 412M | 543M | 528M | 689M | 683M | 780M | 982M | 917M | 1.3B | 1.1B | 1.2B | 1.1B |
| Per Share Data | |||||||||||||
| EPS | 2.85 | 3.09 | 3.17 | 3.41 | 3.00 | 3.66 | 3.21 | 3.61 | 3.59 | 4.25 | 5.53 | 5.89 | 5.31 |
| Owner EPS | 2.15 | 2.55 | 2.32 | 2.37 | 1.88 | 4.47 | 4.73 | 1.33 | 3.06 | 4.26 | 4.90 | 3.58 | 3.65 |
| Book Value | 16.41 | 17.82 | 18.10 | 20.33 | 21.91 | 23.75 | 27.75 | 29.13 | 30.81 | 34.46 | 36.50 | 40.01 | 35.97 |
| Cash Flow/Share | 4.70 | 5.02 | 5.02 | 5.03 | 4.83 | 7.77 | 8.55 | 5.38 | 7.18 | 8.59 | 9.50 | 8.55 | 9.36 |
| Dividends/Share | 1.09 | 1.14 | 1.22 | 1.28 | 1.27 | 1.42 | 1.44 | 1.50 | 1.52 | 1.58 | 1.72 | 1.83 | 1.67 |
| Shares Out. | 67.2M | 64.5M | 64.9M | 64.5M | 64.9M | 66.2M | 66.7M | 67.6M | 66.7M | 66.9M | 67.7M | 66.7M | 73.1M |
| Valuation | |||||||||||||
| P/E Ratio | 20.4 | 20.8 | 20.6 | 22.9 | 28.2 | 29.0 | 39.6 | 31.8 | 29.2 | 28.6 | 28.1 | 20.8 | 24.9 |
| P/FCF | 25.3 | 23.8 | 21.6 | 30.0 | 53.6 | 25.8 | 26.1 | 140.0 | 41.5 | 31.0 | 28.7 | 27.3 | 29.6 |
| EV/EBIT | 12.9 | 13.7 | 13.7 | 15.1 | 21.7 | 21.5 | 27.5 | 25.5 | 20.8 | 22.4 | 22.8 | 18.5 | 21.8 |
| Price/Book | 3.5 | 3.6 | 3.6 | 3.8 | 3.9 | 4.5 | 4.6 | 3.9 | 3.4 | 3.5 | 4.3 | 3.1 | 3.7 |
| Price/Sales | 1.4 | 1.6 | 1.9 | 1.9 | 2.1 | 2.4 | 2.4 | 2.7 | 2.1 | 2.2 | 2.8 | 2.5 | 2.5 |
| FCF Yield | 3.9% | 4.2% | 4.6% | 3.3% | 1.9% | 3.9% | 3.8% | 0.7% | 2.4% | 3.2% | 3.5% | 3.7% | 3.4% |
| Market Cap | 3.9B | 4.1B | 4.2B | 5.0B | 5.5B | 7.0B | 8.5B | 7.8B | 7.0B | 8.1B | 10.5B | 8.2B | 9.7B |
| Avg. Price | 54.92 | 57.69 | 66.75 | 73.53 | 87.51 | 103.09 | 105.93 | 127.46 | 103.39 | 115.73 | 145.72 | 141.16 | 132.36 |
| Year-End Price | 58.14 | 64.26 | 65.33 | 78.09 | 84.60 | 106.31 | 126.97 | 114.90 | 104.76 | 121.74 | 155.61 | 122.78 | 132.36 |
APTARGROUP, INC. passes 5 of 9 quality checks, suggesting mixed fundamentals.
APTARGROUP, INC. trades at 22.5x trailing earnings, compared to its 15-year median P/E of 28.4x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 28.4x vs a median of 28.7x. The company's 5-year average ROIC is 10.2% with a gross margin of 23.3%. Total shareholder yield (dividends + buybacks) is 5.2%. At current prices, the estimated annualized return to fair value is +6.4%.
APTARGROUP, INC. (ATR) has a net profit margin of 10.4%. This is a healthy margin.
APTARGROUP, INC. (ATR) generated $300 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
APTARGROUP, INC. (ATR) has a debt-to-equity ratio of 0.56. This indicates moderate leverage.
APTARGROUP, INC. (ATR) reported earnings per share (EPS) of $5.89 in its most recent fiscal year.
APTARGROUP, INC. (ATR) has a return on equity (ROE) of 15.3%. This indicates the company generates strong returns for shareholders.
APTARGROUP, INC. (ATR) has a 5-year average gross margin of 23.3%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 15 years of financial data for APTARGROUP, INC. (ATR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
APTARGROUP, INC. (ATR) has a book value per share of $40.01, based on its most recent annual SEC filing.
Based on recent SEC filings and earnings disclosures, Management expects continued strength across the pharma portfolio excluding emergency medicine, with prescription division returning to healthy growth in the second quarter and beyond, supported by strong momentum in injectables, systemic nasal drug delivery, and consumer healthcare solutions. The company anticipates sequential margin improvements in beauty and closures segments through the second half of 2026 as production cost headwinds and product mix challenges abate, with full-year adjusted EBITDA margins expected to remain within the company's long-term target range of 32–36%. Capital investments for full year 2026 are expected to be in the range of $260–280 million, and management remains focused on executing a rigorous productivity roadmap to address near-term headwinds while driving further operational efficiencies and supply chain optimization. The emergency medicine destocking headwind of approximately $65 million is expected to be more pronounced in the first half of 2026, with the impact moderating in the second half, after which the company expects to establish a new baseline from which low to mid-single-digit growth is anticipated.
Based on recent SEC filings and earnings calls, APTARGROUP, INC. (ATR) has provided the following forward guidance: Capital investments: $260–280 million (FY2026); Depreciation and amortization expense: $310–320 million (FY2026); Emergency medicine revenue decline: approximately $65 million (FY2026).